LENZ
LENZ Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$236.73M
P/E Ratio
—
EPS
$-3.64
Beta
1.67
52W High
$50.40
52W Low
$6.61
50-Day MA
$9.35
200-Day MA
$22.86
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About LENZ Therapeutics Inc
LENZ Therapeutics Inc is a pioneering biopharmaceutical company dedicated to developing innovative therapies for neurological disorders, specifically addressing critical unmet needs within the central nervous system (CNS). The company employs advanced drug formulation and delivery technologies, reinforced by a robust pipeline of proprietary assets aimed at enhancing patient outcomes. Through strategic partnerships and a commitment to thorough clinical research, LENZ is strategically positioned for growth and aims to become a key player in the biopharmaceutical landscape, capitalizing on opportunities within the dynamic healthcare market.
Fundamentals
| Revenue (TTM) | $20.99M |
| Gross Profit (TTM) | $19.50M |
| EBITDA | $-117.98M |
| Operating Margin | -2322.00% |
| Return on Equity | -49.70% |
| Return on Assets | -31.20% |
| Revenue/Share (TTM) | $0.70 |
| Book Value | $9.07 |
| Price-to-Book | 0.96 |
| Price-to-Sales (TTM) | 11.28 |
| EV/Revenue | 2.645 |
| EV/EBITDA | -7.99 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $31.35M |
| Float | $18.48M |
| % Insiders | 2.65% |
| % Institutions | 107.89% |
Historical Volatility
HV 10-Day
139.91%
HV 20-Day
108.39%
HV 30-Day
96.62%
HV 60-Day
90.71%
HV Rank
77.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($32.00 target)
1
Strong Buy6
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026